Promis Neurosciences

PMN Healthcare Biotechnology

In the quarter to June 2026, EPS grew 82.3% and free cash flow fell 169.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

8.15 0.55 −6.32%
Market cap
$78.0M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
3/9
Altman Z
−78.86
Beneish M
−7.40
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(172.30%) (115.73%) (521.60%) (355.80%)

+8 more TTM periods

ROA
(127.57%) (100.21%) (282.76%) (127.40%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(85.35%) (68.84%) 3,230.77% (316.67%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(4.61) (5.45) (16.00) (14.10)
Free Cash Flow
(42.11) (35.58) (28.12) (27.55)
Other line items

Show all line items

Columns are period end dates